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The O-GlcNAc modification is proposed to be
a nutrient sensor with studies suggesting that global
increases inO-GlcNAc levels cause insulin resistance
and impaired glucohomeostasis. We address this
hypothesis by using a potent and selective inhibitor
of O-GlcNAcase, known as NButGT, in a series of
in vivo studies. Treatment of rats and mice with
NButGT, for various time regimens and doses,
dramatically increases O-GlcNAc levels throughout
all tissues but does not perturb insulin sensitivity or
alter glucohomeostasis. NButGT also does not affect
the severity or onset of insulin resistance induced by
a high-fat diet. These results suggest that pharmaco-
logical increases in global O-GlcNAc levels do not
cause insulin resistance nor do they appear to disrupt
glucohomeostasis. Therefore, the protective benefits
of elevatedO-GlcNAc levelsmaybeachievedwithout
deleteriously affecting glucohomeostasis.
INTRODUCTION
Insulin activates signaling pathways that maintain glucohomeo-
stasis in many tissues but most importantly in muscle, liver, and
adipose tissue. In recent years, there has been a growing
appreciation that activation of these signaling pathways can be
fine-tuned by additional mechanisms. Nutrient availability has
been one focus of research in this area, with numerous studies
demonstrating a link between nutrient availability and insulin
sensitivity (Liu et al., 2008; Schenk et al., 2008; Towler and
Hardie, 2007; Wang and Proud, 2009). Hyperglycemia has long
been known to cause insulin desensitization (Kim et al., 2001;
Nawano et al., 2000; Nelson et al., 2002; van Putten and Krans,
1985). The effects of chronically elevated blood glucose levels
on various tissues clearly play an important role in the self-ampli-
fying nature of type II diabetes mellitus; however, the molecular
mechanism(s) by which glucose influences insulin sensitivity
is not fully understood and continues to be a topic of consider-
able interest.
A small percentage of glucose enters the hexosamine
biosynthetic pathway (HBSP) to make UDP-GlcNAc, which isChemistry & Biology 17, 949–9in turn used for the biosynthesis of UDP-GalNAc and
CMP-NeuAc, and together these three molecules are used by
various cellular glycosyltransferases for the biosynthesis of
many different glycoconjugates. Numerous studies have shown
that increased cellular UDP-GlcNAc levels correlate with insulin
resistance (Hebert et al., 1996; Marshall et al., 1991; Rossetti
et al., 1995). One form of glycosylation that depends exclusively
on UDP-GlcNAc is the intracellular glycosylation of nucleocyto-
plasmic proteins with a single b-O-linked N-acetylglucosamine
(GlcNAc) residue. Levels of O-GlcNAc on proteins are regu-
lated by two enzymes: O-GlcNAc transferase (OGT) catalyzes
the installation of GlcNAc onto specific serine and threonine
residues of target proteins via a b-glycosidic linkage, while
O-GlcNAcase (OGA) removes the modification. A leading
hypothesis for the cellular role(s) of the O-GlcNAc modification
is that an interplay between O-GlcNAc and phosphorylation
exists to fine-tune cellular signaling pathways. As the O-GlcNAc
modification has been detected on a number of proteins involved
in the insulin signaling cascade, such as Akt (Park et al., 2005),
IRS-1 (Ball et al., 2006), and FoxO1 (Housley et al., 2008),
elevated O-GlcNAc levels have the potential to be a molecular
mechanism that links hyperglycemia to insulin resistance.
Based on a number of in vivo studies, elevation of cellular
O-GlcNAc levels have been proposed to cause insulin resistance
or perturb glucohomeostasis. The most compelling of these
studies observed insulin resistance resulting from adenoviral-
mediated overexpression of OGT in the liver (Dentin et al.,
2008; Yang et al., 2008) or by transgenic overexpression of
OGT inmuscle and fat tissue (McClain et al., 2002). As discussed
in Macauley et al. (2010) (this issue of Chemistry & Biology),
increasing O-GlcNAc levels in a classical adipocyte model using
two structurally distinct OGA inhibitors does not support a role
for elevated O-GlcNAc playing an independent role in the devel-
opment of insulin resistance. Therefore, the role that increased
O-GlcNAc levels play in the development of insulin resistance
in cultured cells is controversial and investigating the role of
O-GlcNAc in the context of an intact endocrine system might
provide a more faithful environment in which to discern effects
arising from increasedO-GlcNAc levels. Accordingly, we felt that
exploring the effects of increased O-GlcNAc levels induced by
the inhibition of OGA in vivo would be an important contribution.
The use of OGA inhibitors would have the advantage that they
could aid understanding of the temporal relationship between
cellularO-GlcNAc levels and insulin resistance as well as to eval-
uate if this process is reversible. On the other hand, if no insulin58, September 24, 2010 ª2010 Elsevier Ltd All rights reserved 949
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observed this would indicate O-GlcNAc levels, stemming from
inhibition of OGA, are not an independent mechanism leading
to insulin resistance. Such a finding would be notable since it
would open the door to detailed study on the independent phys-
iological functions of increased O-GlcNAc levels. Because in
Macauley et al. (2010), we find that two structurally distinct inhib-
itors both have similar effects on O-GlcNAc levels and signaling
pathways, we initiated studies in rodents using the selective
OGA inhibitor known as NButGT.
Here,wefind thatNButGTelevatesO-GlcNAc levels throughout
all tissues tested of Sprague-Dawley rats andC57BL/6Jmice but,
surprisingly, animals treated for a prolonged period of time with
high doses of NButGT are healthy and show no signs of insulin
resistance as determined by glucose tolerance tests and hyperin-
sulemiceuglycemicclamp.Therefore, studies inculturedcellsand
in vivo appear to be in agreement that selective inhibition of OGA
doesnot cause insulin resistance.Nevertheless, thesefindingsare
not in harmony with studies overexpressing OGT (Dentin et al.,
2008; McClain et al., 2002; Yang et al., 2008). A discussion is pre-
sented on some factors that might account for this discrepancy
between pharmacological and genetic methods used to increase
O-GlcNAc levels. The findings of this study open the intriguing
possibility of elevating O-GlcNAc levels throughout an entire
organism, by using a small molecule inhibitor of OGA, not only
for advancing our understanding of the in vivo roles of the
O-GlcNAc modification, but also for beneficial purposes such as
exploiting the protective effect that elevated O-GlcNAc levels
have been shown to confer to cells and tissues (Ngoh et al.,
2008; Zachara et al., 2004; Zou et al., 2007).
RESULTS AND DISCUSSION
The effect of elevatedO-GlcNAc levels, induced by a small mole-
cule inhibitor of OGA, on glucohomeostasis in vivo has never
been investigated. We felt that exploring the effects of the
OGA inhibitor NButGT in vivo, where the entire endocrine system
is operational, would be a valuable study complimenting existing
reports in which O-GlcNAc levels have been modulated using
genetic approaches (Dentin et al., 2008; McClain et al., 2002;
Yang et al., 2008). Two recent studies have suggested that
such a study might be feasible; two different small molecule
OGA inhibitors, PUGNAc and Thiamet-G, have been shown to
increase global O-GlcNAc levels in rodents (Yuzwa et al., 2008;
Zou et al., 2007). We felt that NButGT would be an excellent
candidate for these studies since (1) it would enable us to
compare our results with previous data using cultured adipo-
cytes (Macauley et al., 2008), (2) NButGT is highly selective for
OGA (Macauley et al., 2005), (3) it can be readily synthesized
on a large multigram scale, and (4) another structurally distinct
inhibitor described in Macauley et al. (2010) reveals the same
effects on cells as NButGT. Conversely, we felt that PUGNAc
would be a poor choice to use in vivo since it does not penetrate
all tissues (Zou et al., 2007), inhibits the functionally related HexA
and HexB enzymes whose dysfunction leads to lysosomal
storage disorders (Triggs-Raine et al., 2001), and results in
responses that differ from two other classes of OGA inhibitor in
cultured cells, and until very recently (Goddard-Borger and
Stubbs, 2010) access to significant quantities of PUGNAc was950 Chemistry & Biology 17, 949–958, September 24, 2010 ª2010 Elnot feasible. On the basis of these careful considerations, we
undertook such studies using NButGT in rodents.
Administration of NButGT Elevates O-GlcNAc Levels
in Sprague-Dawley Rats
Preliminary experiments were carried out to assess the effective-
ness of NButGT in SD rats. We were particularly interested in the
time-dependent effect of NButGT on O-GlcNAc levels since
longer term studies would require a carefully considered dosing
regimen tomaintain increasedO-GlcNAc levels through the entire
course of the study. To investigate this issue, SD rats were given
an intravenous injection of NButGT at a concentration of
50 mg$kg-1 and sacrificed at various times postinjection. Evalua-
tion of homogenized brain and muscle tissues by western blot
analyses using the CTD110.6 anti-O-GlcNAc antibody (Comer
et al., 2001) reveals that O-GlcNAc levels are increased in
a time-dependent manner in response to NButGT administration
(Figures 1A and 1B). Increased O-GlcNAc levels are observed
after 1 hr and return to approximately basal levels after 24 hr.
A study of the dose-dependent increases in O-GlcNAc levels in
brain revealed that 5 mg$kg-1 of NButGT increases O-GlcNAc
levels (Figure1C). Pharmacokinetic evaluationofNButGT inblood
reveals that NButGT clearance follows an exponential decay with
a half-life of 30 min (see Figure S1 available online). Therefore, it
appears that clearance of NButGT from the blood is rapid.
Tomaintain increasedO-GlcNAc levels throughout a 24hr period,
we reasoned that a slow continuous dose of NButGT would be
preferable; therefore, we investigated the effect of NButGT incor-
porated into the animal chow. A 3 day oral treatment using
100mg$kg-1$day-1 ofNButGT, incorporated intochow, produced
elevated levels of O-GlcNAc-modified proteins in muscle, fat,
brain, and pancreas (Figures 1D–1G), as well as liver and spleen
tissues (Figure S1). In a separate study, the dose of NButGT in
the food was varied and, based on analyses of brain and muscle
tissue, it appears that the oral dose-dependency of O-GlcNAc
levels were approximately linear up to the largest dose tested of
100mg$kg-1$day-1 (Figures 1H and 1I). Collectively, these results
show that intravenous or oral administration of NButGT acts
in vivo throughout all tissues tested to elevate O-GlcNAc levels
in both a dose- and time-dependent manner.
Acute Treatment of Rats with NButGT Does Not Alter
Glucose Tolerance
We next turned our attention to what effect NButGT might have
on glucohomeostasis. Six-week-old male SD rats were given
a 50 mg$kg-1 tail vein injection of NButGT or vehicle and, after
7 hr, we carried out intravenous glucose tolerance tests (IVGTT).
Glucose tolerance was unaffected (Figure 2A) even though
animals treated with the inhibitor had dramatic increases in
levels ofO-GlcNAc-modified proteins (Figures 2B and 2C). Addi-
tionally, resting blood glucose levels, which are a classic
measure of insulin sensitivity and reflective of the severity of
insulin resistance (Muniyappa et al., 2008), were unaffected by
inhibitor treatment and the resulting increased global O-GlcNAc
levels (Figure 2A). This finding differs somewhat from the findings
of Dentin et al. (2008) which showed that adenoviral-mediated
overexpression of OGT in liver caused elevated blood glucose
levels in animals fed ad libitum. Also differing from our findings
is that Yang et al. (2008) reported that when OGT wassevier Ltd All rights reserved
Figure 1. NButGT Globally Elevates
O-GlcNAc Levels in Sprague-Dawley Rats
through Intravenous or Oral Delivery
(A and B) Nine rats were treated with NButGT via a
tail vein injection at a dose of 50mg$kg-1 and sacri-
ficedat various timespostinjectionandanalyzed for
O-GlcNAc content in the brain (A) and muscle (B)
tissue. (C) Sprague-Dawley rats were given varying
doses of NButGT via a tail vein injection and 7 hr
after delivery of the inhibitor, the animals were
sacrificed, tissues were collected, and O-GlcNAc
content in the brain was analyzed.
(D–G) Two rats were treated with either 0 or
100 mg$kg-1$day-1 of NButGT incorporated into
their chow for 3 days and analyzed for O-GlcNAc
content in the brain (D), muscle (E), fat (F), and
pancreas (G) tissues.
(H and I) NButGT elevatesO-GlcNAc levels in brain
(H) and muscle (I) in a dose-dependent manner
when incorporated into thechowand fed for 3days.
For all blots, the upper panel represents blots
probed with the CTD110.6 anti-O-GlcNAc anti-
body and the lower panel represents blots probed
with anti-b-actin as a loading control. For addi-
tional experiments supporting data from this
figure, see Figure S1.
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infection, insulin sensitivity was diminished but elevated blood
insulin levels masked any effect on resting blood glucose levels
and glucose tolerance. In both these studies, the approach to
increasing O-GlcNAc levels was quite different in that genetic
methods were used to overexpress OGT in a targeted tissue.
Considering this difference and the possibility that insulin resis-
tance may take more time to develop, we therefore undertook
studies in which insulin levels were monitored, animals were
dosed for longer times, and more rigorous measures of glucoho-
meostasis were used.
NButGT Does Not Perturb Activation of the Insulin
Signaling Pathway in Liver and Muscle
The results presented thus far have all probed functional
measures of insulin resistance. Previous results using overex-Chemistry & Biology 17, 949–9pression of OGT or PUGNAc have suggested that increased
O-GlcNAc levels prevent phosphorylation of key signaling mole-
cules in the insulin signaling cascade such as IRS-1 and Akt
(Dentin et al., 2008; Yang et al., 2008). To look for insulin resis-
tance at the molecular level, SD rats were treated orally for
3 days with 1000 mg$kg-1$day-1 of NButGT. On the third day,
the food was withdrawn overnight and NButGT was placed in
the water at the same dose in order maintain O-GlcNAc levels.
The following day, animals were given a 1 g$kg-1 tail vein injec-
tion of glucose or PBS as a control. After 10 min, the animals
were sacrificed and the appropriate tissues were collected for
analysis by western blotting. NButGT treatment, and the associ-
ated increases in O-GlcNAc levels, did not impair insulin-stimu-
lated activation of Akt, IRS1, or FoxO1 in the liver while Akt acti-
vation was also not impaired in muscle or fat tissues (Figure 3).
These results are in keeping with the functional measures ofFigure 2. An Acute Treatment with NButGT
Does Not Perturb Glucose Tolerance in SD
Rats
(A) Food was withheld from animals overnight and
animals were given a 50 mg$kg-1 injection of
NButGT (circles) or vehicle (squares) (n = 4). The
following morning, 16 hr later, another injection of
NButGT or vehicle was given. Seven hours later,
a time at which increases in levels of O-GlcNAc-
modified proteins are maximal, an IVGTT was per-
formed using a 1 g$kg-1 bolus IV injection of
glucose (t = 0).
(B and C) Western blot analyses of homogenized
brain (B) and muscle (C) tissue reveal that animals
treated with NButGT (+) had elevated levels of
O-GlcNAc-modified proteins compared with con-
trol animals () (upper panel). Equivalent protein
loading is demonstrated using an anti-b-actin anti-
body (lower panel).
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Figure 3. NButGT Does Not Perturb Activa-
tion of Key Insulin Signaling Molecules
(A–C) Four SD rats were treated for 3 days with
1000 mg$kg-1$day-1 of NButGT. Four animals
were also treated as controls. On the fourth day,
the animals were given either a tail vein injection
of 1 g$kg-1 of glucose or PBS as a control.
Precisely 10 min later, the animals were sacrificed
and the liver, muscle, and adipose tissues were
harvested for western blot analyses.Western blots
from homogenized liver (A), muscle (B), and
adipose (C) tissue were probed with the indicated
antibodies. Densitometry of the relevant blots is
shown directly to the right; in no cases does
NButGT cause a statistically significant difference
in the insulin-mediated phosphorylation of these
signaling molecules.
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that NButGT does not prevent insulin-stimulated activation of
Akt in 3T3-L1 adipocytes (Macauley et al., 2008).Two-Week Treatment of Rats with NButGT
Does Not Alter Glucose Homeostasis
Eight rats were dosed orally for 2weekswith NButGT at a dose of
200 mg$kg-1$day-1, a dose that would maintain O-GlcNAc levels
throughout a 24 hr period, based on our pharmacokinetic anal-
ysis. Eight weight and age-matched animals were treated as
controls. On day 14 of the treatment, an IVGTT was performed
and the results show that NButGT treatment does not alter the
response to the glucose challenge nor does it affect resting
blood glucose levels (Figure 4A). Significantly, we observe no
differences in plasma insulin levels between control and treated
animals before or after the glucose challenge (Figure 4B). To
rigorously probe for the presence of insulin resistance in periph-
eral tissues we repeated the two week treatment study on six
experimental and six control animals and carried out hyperinsu-
lemic-euglycemic clamp experiments—the gold standard for
measurement of insulin sensitivity of peripheral tissues in vivo
(Muniyappa et al., 2008). For this study, 20 mU$min-1$kg-1 of
insulin was infused throughout the 2 hr experiment to ensure
that hepatic glucose output was not an interfering variable (Ros-
setti and Giaccari, 1990). Consistent with the findings of the
IVGTT, resting blood glucose levels, and insulin levels, these
clamp experiments also did not reveal differences between the
insulin sensitivity of peripheral tissues from treated and control
groups (Figure 4C).
We had considered that the required fasting of animals over-
night prior to the IVGTT and clamp studies might limit the acute
exposure of the animals to NButGT prior to testing and thus
cause O-GlcNAc levels to return to basal levels. To circumvent
this problem, NButGT was added to the water supply of the
treated animals during the night preceding testing to ensure
increased O-GlcNAc levels were maintained at the time of the
experiments; a prior study with the NButGT analog Thiamet-G
had showed that it was orally available when administered
through the water supply of the animals (Yuzwa et al., 2008).
Following these experiments, tissues from several postclamp
animals were analyzed and the levels of O-GlcNAc-modified
proteins in the brain, muscle, fat, and liver were elevated in
NButGT-treated animals (Figures 4D–4G), and these results952 Chemistry & Biology 17, 949–958, September 24, 2010 ª2010 Elshow that treated animals have dramatically elevated O-GlcNAc
levels. In addition, immunoprecipitation of Sp1 from the tissues
of three control and treated animals shows thatO-GlcNAc levels
are elevated on this protein (Figure 4H).Administration of NButGT for 8 Months Does Not Result
in Insulin Resistance
Given these findings, we considered that the onset of insulin
resistance and type II diabetes is typically slow. Chronic eleva-
tion of O-GlcNAc levels, rather than acute increases, could
cause a gradual adaptation within tissues giving rise to a physio-
logically realistic slow onset of insulin resistance. This hypoth-
esis seems consistent with observations that acute fluctuations
in dietary intake cause oscillations in O-GlcNAc levels (Akimoto
et al., 2001, 2007) and that prolonged excess nutrient intake
could cause gradual accumulation of insults via O-GlcNAc and
thus trigger insulin resistance. To evaluate the effects of chronic
elevation of O-GlcNAc levels, we carried out a long-term study
using six male SD rats treated with 200 mg$kg-1$day-1 of
NButGT and eight control rats. Resting blood glucose levels,
food and water consumption, and the body weight of these
animals, all of which are measures that can reveal a diabetic
phenotype, were monitored closely over the course of the study.
Surprisingly, no differences were observed between the two
groups for any of these variables (Figure S2). As well, no differ-
ences were observed in triglycerides, free fatty acids, and leptin,
or in the weights of individual organ weights upon sacrifice
(Figure S2). Treated animals did not show any sign of discomfort
or any abnormal behavior as monitored during regular handling.
Following 8 months of treatment, animals were subjected to an
IVGTT and, later, a hyperinsulemic-euglycemic clamp. We
observed no differences between groups with respect to
glucose tolerance, insulin secretion during IVGTT, or insulin
sensitivity (Figures 5A–5C). The advanced age of these animals
and their natural variation in weight gave rise to expected levels
of variation in the clamp results (James et al., 1985).
For this study, the inhibitor was not delivered in the water
during the overnight fast since the aim was to evaluate
differences stemming from chronic elevation ofO-GlcNAc levels
and not the potential acute effects of increasedO-GlcNAc levels.
Despite this overnight fasting and consequent 19 hr withdrawal
of inhibitor, significant increases in the levels ofO-GlcNAc-modi-
fied proteins were still observed in brain and muscle (Figures 5Dsevier Ltd All rights reserved
Figure 4. Two Week Treatment of Rats
with NButGT Does Not Perturb Glucoho-
meostasis
(A–C) Eight animals were treated orally with
NButGT at a dose of 200 mg$kg-1$day-1 (circles)
for 2 weeks while eight control animals were
treated identically except that no inhibitor was
added to their food (squares). (A) An IVGTT was
performed using a 1 g$kg-1 bolus IV injection of
glucose (t = 0) and blood glucose levels were
analyzed as a function of time. (B) Blood insulin
levels throughout the glucose challenge were
analyzed for insulin content. (C) A separate set of
animals (n = 6) were treated identically for 2 weeks
and subjected to a hyperinsulemic-euglycemic
clamp using an insulin infusion rate of
20 mU$min-1$kg-1. Data are represented as mean
± SD. Under no conditions are there differences
observed between the treated and control groups.
(D–G) Rats treated with NButGT for 2 weeks have
elevated O-GlcNAc levels. Analysis of O-GlcNAc
levels in brain (D), muscle (E), fat (F), and liver (G)
tissue from treated (+) and control () animals
using CTD110.6 (upper panels). Equivalent protein
loading is demonstrated in the lower panels using
an anti-b-actin antibody (lower panels).
(H) Immunoprecipitation of Sp1 from the spleen of
2 week treated animals. Immunoprecipitates were
probed for Sp1 and the RL2 anti-O-GlcNAc anti-
body.
For additional experiments supporting data from
this figure, see Figure S2.
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As well, immunoprecipitation of Sp1 revealed that its O-GlcNAc
levels were elevated by inhibitor treatment (Figure 5F). Notably,
these differences in O-GlcNAc levels are observed despite an
approximately 3-fold increase in OGA levels in treated versus
control animals while no significant change in OGT levels were
observed (Figure S2). These findings indicate that pharmacolog-
ical interventions maintain increased O-GlcNAc levels over the
long term, even with the elevation in OGA levels observed in
treated animals. The increases in O-GlcNAc levels observed in
the long-term study, even after 19 hr withdrawal of the inhibitor,
are as large as those seen under hyperglycemic conditions
(Akimoto et al., 2001; Walgren et al., 2003) or in diabetic animals
(Akimoto et al., 2007).
Prolonged Global Increases in O-GlcNAc Levels
Do Not Cause b-Cell Toxicity
Alterations in O-GlcNAc levels have also been proposed to
mediate impaired glucose-stimulated insulin secretion (GSIS)Chemistry & Biology 17, 949–958, September 24, 2010since elevated O-GlcNAc levels have
been correlated with decreased GSIS
(Akimoto et al., 2007; Gao et al., 2000;
Liu et al., 2000). Other studies, however,
do not support this hypothesis (Kaneto
et al., 2001; Zraika et al., 2006). A further
report showed that elevating O-GlcNAc
levels resulted in increased insulin
production rather than impaired insulinsecretion (Andrali et al., 2007). It is difficult to reconcile these find-
ings, which appear to suggest opposing effects, but it is notable
that several of these studies have usedenzyme inhibitorswith es-
tablished off-target effects such as PUGNAc and streptozotocin.
In an effort to clarify these conflicting observations, we examined
the long-term treated animals for any signs of b cell toxicity.
Following the 8 month study, the pancreas of several treated
and control animals were analyzed by immunohistochemistry
(IHC) (Figure S2). Consistent with the western blot analyses
from the brain and muscle tissues of the long-term treated
animals, higher O-GlcNAc levels were observed in the pancreas
of NButGT-treated animals. Qualitative IHC analysis using an
anti-insulin antibody and hematoxylin staining of many pancre-
atic sections revealed no apparent differences in themorphology
or number of islets between the groups (Figure S2). These find-
ings are in keeping with our results showing that global increases
ofO-GlcNAc levels do not give rise to differences in fasting blood
insulin levels nor do they alter insulin secretion in response to
glucose challenge (Figures 4B and 5B).ª2010 Elsevier Ltd All rights reserved 953
Figure 5. Eight Month Treatment of Rats with
NButGT Does Not Perturb Glucohomeostasis
(A–C) Six animals were administered NButGT orally at
a dose of 200 mg$kg-1$day-1 (circles). Eight control
animals were also treated identically except no inhibitor
was added to their food (squares). (A) An IVGTT was per-
formed using a 1 g$kg-1 bolus IV injection of glucose
(t = 0) and blood glucose levels were analyzed as a function
of time. (B) Blood insulin levels throughout the glucose
challenge were determined. (C) A week later, the animals
were subjected to a hyperinsulemic-euglycemic clamp
using an insulin infusion rate of 3 mU$min-1$kg-1. Data rep-
resented as mean ± SD.
(D and E) Analysis of O-GlcNAc levels in brain (D) and
muscle (E) from treated (+) and control () animals using
CTD110.6 (upper panels). Equivalent protein loading is
demonstrated with an anti-b-actin antibody (lower panels).
(F) Immunoprecipitation of Sp1 from the spleen of animals
treated with (+) and without () NButGT for 2 weeks.
Immunoprecipitates were probed for Sp1 and RL2.
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Glucohomeostasis or Elevate the Ganglioside GM2
To rule out the possibility that the dose of NButGT used in the
previous studies (200 mg$kg-1$day-1) was not high enough to
observe an effect on glucohomeostasis, four SD rats were
treated with a high dose (1000 mg$kg-1$day-1) of NButGT. After
2 months of treatment, these animals, along with the appropri-
ately treated control animals, were subjected to an IVGTT.
Once again, no difference in resting blood glucose levels or
glucose tolerance was observed (Figure 6A). In this study, for
the overnight fasting period the inhibitor was placed in the water
of the treated animals at the same dose and this did give rise to
dramatically elevated O-GlcNAc levels (Figure 6B).
An additional aim of this particular study was to determine if
high levels of NButGT might accumulate and inhibit functionally
related enzymes of OGA. In addition to OGA, mammals have
several other functionally related enzymes that both cleave
terminal b-linked N-acetylglucosamine residues and use the
same enzymatic mechanism (Macauley and Vocadlo, 2009).
HexA and HexB are isozymes that reside in the lysosome and
cleave GlcNAc and GalNAc from a variety of glyconjugates.
The best characterized substrate for these lysosomal b-hexosa-
minidases is the ganglioside GM2. Mutations of these enzymes
in humans (Triggs-Raine et al., 2001) or deletion of either of the
enzymes in mice (Sango et al., 1995; Yamanaka et al., 1994)
results in a slow accumulation of GM2 in the lysosome eventually
leading to lysosomal storage disorders known as Tay-Sachs and
Sandhoff disease and a dramatically shortened life span. The
most commonly used inhibitor of OGA, PUGNAc, suffers from
the shortcoming that it is an equally potent inhibitor of both
OGA and the lysosomal b-hexosaminidases. This nonspecific
effect results in both elevated O-GlcNAc levels and GM2 levels
in cultured neuroblastoma cells (Stubbs et al., 2009) as well as954 Chemistry & Biology 17, 949–958, September 24, 2010 ª2010 Elsevier Ltd All righBV2 microglia cells (Ho et al., 2010). In contrast,
NButGT was designed to deliver selectivity for
OGA over the lysosomal b-hexosaminidases
(Macauley et al., 2005). Indeed, the 600-fold
selectivity of NButGT for OGA has been shownto prevent it from increasing GM2 levels in cultured cells (Stubbs
et al., 2009). To evaluate whether NButGT acts to elevate GM2
levels over prolonged dosing periods, gangliosides were ex-
tracted from brain tissue of animals in the 2 month high-dosing
study. Although gangliosides are found in all tissues, the brain
is particularly rich in gangliosides, making it a valuable reporter
for ganglioside levels. As shown in Figure 6C, NButGT-treated
SD rats did not exhibit increased GM2 levels in their brains.
In comparison, Hexb/ mice show dramatic accumulation of
GM2 levels to levels at least 10-fold above healthy animals at
2 months of age (Andersson et al., 2004). These results under-
score the selectivity of NButGT over the functionally related
HexA and HexB and provide good evidence that this selectivity
extends to in vivo models even at very high doses.
NButGT Does Not Perturb Glucose Homeostasis in Mice
or Affect the Onset or Severity of Insulin Resistance
Induced by a High-Fat Diet
All experiments described thus far were carried out in SD rats;
however, in some experimental paradigms, variance within
rodents is observed. For instance, a percentage of SD rats are
resistant to weight gain when placed on a high-fat diet (Levin
et al., 1987). To evaluate whether the absence of any observable
effect on insulin resistance that we observe when treating SD
rats with NButGT is a general phenomenon in rodents, we tested
NButGT in C57BL/6J mice. As the metabolism of mice is faster
than rats and generally leads to faster clearance of small mole-
cules (Hayes, 2007), we used the higher dose of NButGT
(1000 mg$kg-1$day-1) that was used in the experiments involving
SD rats. Twelve mice were treated with NButGT for 3 months by
incorporating this inhibitor into their chow to provide a dose of
1000 mg$kg-1$day-1. Resting blood glucose and insulin levels
were measured at 4, 8, and 12 weeks after commencement ofts reserved
Figure 6. TwoMonthHigh-Dose(1000mg$kg-1$day-1)
Treatment of Rats with NButGT Does Not Per-
turb Glucose Tolerance or GM2 Levels
(A) An IVGTT was performed on four treated (circles) and
four control (squares) animals using a 1 g$kg-1 bolus IV
injection of glucose (t = 0) and blood glucose levels were
analyzed as a function of time.
(B) Analysis of O-GlcNAc levels in the brain of treated (+)
and control () animals using the CTD110.6 anti-O-
GlcNAc antibody (upper panel). Equivalent protein loading
is demonstrated with an anti-b-actin antibody (lower
panel).
(C) Analysis of the ganglioside GM2 levels in the brain of
treated (+) and control () animals. The TLC plate was
stained with resorcinol and represents total gangliosides
from the brain. The right panels represent a magnified
image of the band corresponding to GM2 and another
band as a loading control. The panel for GM2 was con-
trasted for display and densitometry. Densitometric anal-
ysis of the GM2 band relative to the load control band
reveals no statistical difference in levels of GM2 levels
between the two groups.
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parameters between treated and untreatedmice (Figures 7A and
7B). Following 12 weeks, an oral glucose tolerance test (OGTT)
was carried out using gavage of 1 g$kg-1 of glucose. We find
that glucose clearance was unaffected by treatment with
NButGT despite clear increases in global O-GlcNAc levels
(Figure 7C).
The studies presented thus far present strong evidence that
increased global O-GlcNAc levels in vivo, induced by NButGT,
do not on their own cause insulin resistance. Nevertheless, it
remained a distinct possibility that elevated O-GlcNAc levels
may play a role in exacerbating the speed of onset and/or the
severity of insulin resistance when other pathways are malfunc-
tioning. A common method for inducing insulin resistance
in vivo is through diet-induced obesity (DIO) using a high-fat
diet (HFD). We therefore used a HFD in conjugation with
NButGT, to evaluate whether dysfunction of other pathways
is required to observe an effect from increased O-GlcNAc levels
on glucohomeostasis. This study was carried out in parallel
with, and using the same dosing regimen, as the previous study
using healthy mice. As shown in Figure 7A, the HFD induced
a gradual elevation in resting blood glucose levels. The onset
or severity of insulin resistance, judged in this manner, was
not affected by treatment with NButGT. The resting blood
glucose levels that we observe for mice placed on a HFD for
12 weeks closely matches values observed by others for an
equivalent length of treatment (Ohtsubo et al., 2005). The rest-
ing blood insulin levels also remained unaffected by inhibitor
treatment throughout the course of the study, with a 9-fold
increase occurring after 12 weeks in HFD mice as compared
with healthy mice. An OGTT was carried out and revealed
that mice on a high-fat diet cleared glucose slower (Figure 7C)
when compared with control animals; however, there was no
difference in glucose clearance arising from NButGT treatment
and consequent elevation of O-GlcNAc. Weight gain in both
healthy and HFD mice was not affected by NButGT (Figure 7D).
In order to clarify whether the mode of dosing in this study
produced increased O-GlcNAc levels throughout a 24 hrChemistry & Biology 17, 949–9period, an animal from each control and treated group were
sacrificed at three different time points throughout the day
(8 a.m., 4 p.m., and 11 p.m.). In both muscle and liver tissues,
O-GlcNAc levels were elevated in the treated animals at all
three time points (Figures 7E and 7F), supporting this oral
dosing regimen as a means of generating sustained increases
in O-GlcNAc levels.
Overall, the results of the studies we describe here differ with
previous findings in which genetic methods have been used to
overexpress OGT. Those studies have proposed that increased
O-GlcNAc levels induce insulin resistance and/or disrupt gluco-
homeostasis (Dentin et al., 2008; McClain et al., 2002; Yang
et al., 2008). There are obvious differences between using small
molecules to increase O-GlcNAc levels and using genetic
methods (Knight and Shokat, 2007) and a consideration of these
differences is prudent. Various possible scenarios as to why
genetic and chemical methods of altering O-GlcNAc levels give
rise to different effects in vivo include: (1) increases in global
O-GlcNAc levels may result in increased hepatic output and
therefore mask certain physiological measurements, (2) the
cycling rate of O-GlcNAc on various proteins may play a role in
nutrient sensing, (3) NButGTmay not gain access to all compart-
ments and may therefore not affect O-GlcNAc levels on nutrient
sensing proteins, and (4) OGT may have noncatalytic protein
scaffolding roles that are independent of increased O-GlcNAc
levels. A discussion of the likelihood of each of these possible
scenarios is presented in the Supplemental Information. These
considerations should serve to guide future experiments that
may provide insight into the biological roles of O-GlcNAc and/
or OGT.
SIGNIFICANCE
We describe the first studies to our knowledge in which
global O-GlcNAc levels are increased throughout a whole
organism for an extended period of time using anOGA inhib-
itor in order to evaluate the effects on glucohomeostasis.
To realize this aim, we have used NButGT, an inhibitor of58, September 24, 2010 ª2010 Elsevier Ltd All rights reserved 955
Figure 7. Three Month Treatment of Mice
with 1000 mg$kg-1$day-1 NButGT Does Not
Perturb Glucohomeostasis
(A) Resting blood glucose levels of treated and
control animals on a normal diet (ND) or high-fat
diet (HFD) at 4, 8, and 12 weeks after starting
dosing (n = 12).
(B) Resting blood insulin levels at 4, 8, and
12 weeks after starting dosing (n = 12).
(C) An oral glucose tolerance test (OGTT) was per-
formed after 13 weeks of treatment (n = 12 per
group).
(D) Growth rate of mice on a normal diet (ND) or
high-fat diet (HFD). Body weight was recorded
once a week over the course of the study (n = 12
per group).
(E and F) 1000 mg$kg-1$day-1 of NButGT main-
tains elevated O-GlcNAc levels throughout
a 24 hr cycle in the muscle (E) and liver (F) of
mice on a normal diet (ND) or high-fat diet (HFD).
One animal from all four groups was sacrificed at
8 a.m., 4 p.m., and 11 p.m. and analyzed by
western blot for O-GlcNAc levels (upper panel)
and for protein loading using an anti-b-actin anti-
body (lower panel).
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a complex phenotype stemming fromconcomitant inhibition
of functionally related enzymes. We investigated multiple
time regimens ranging from 1 day to 8 months of treatment
in mice and rats. No signs of functional insulin resistance
or perturbed glucohomeostasis were observed as assessed
by resting blood glucose and insulin levels, hyperinsulemic-
euglycemic clamps, and glucose tolerance tests. Consistent
with the absence of any observable effect on functional
measures of insulin sensitivity, no signs of insulin resistance
at the molecular level are observed from NButGT treatment.
The findings described here differ somewhat from previous
studies in which OGT has been overexpressed in vivo. The
collective observations, including those described here,
however offer several interesting hypotheses that could be
reconciled and lead to greater clarity in the area of
O-GlcNAc. Notably, the results here are intriguing in the
context of the proposed beneficial effects of increased
O-GlcNAc levels on survival of cells and tissues faced with
various stresses (Ngoh et al., 2008; Zachara et al., 2004;
Zou et al., 2007). Indeed, the studies we describe here
open the possibility that increasedO-GlcNAc levels, induced
using inhibitors of OGA, could be harnessed for therapeutic
benefit without disruption of glucohomeostasis. Perhaps956 Chemistry & Biology 17, 949–958, September 24, 2010 ª2010 Elsevier Ltd All rights resemost significantly, this study offers
guidance for future in vivo studies de-
signed to further our understanding
of this unique form of glycosylation.
EXPERIMENTAL PROCEDURES
General
All solutions containing salts and buffers were
made from materials obtained from Bioshop
unless otherwise noted. The CTD110.6 anti-O-
GlcNAc, anti-b-actin, and anti-OGT antibodieswere purchased fromCovance,
Sigma, and Santa Cruz, respectively. All secondary antibodies were obtained
from Santa Cruz.
Animal Care
All experiments carried out on animals were approved by the university animal
care committee of Simon Fraser University. For studies with rats, 5-week-old
Sprague-Dawley rats (Charles River) were acclimatized for 1 week prior to
experimentation. For studies with mice, C57BL/6J mice (Charles River) were
obtained at 3 weeks of age and allowed to acclimatize for 1 week prior to
experimentation. Rooms were kept at 22C and maintained on a constant
12 hr light/12 hr dark cycle. Food and water were replaced every 2–3 days.
See Supplemental Experimental Procedures for details on the synthesis of
NButGT. Following the completion of experiments, animals were sacrificed
by either a 100 mg$kg-1 intravenous injection of euthanyl (Bimeda-MTC) or
with CO2. Tissues were collected immediately after sacrifice, flash frozen in
liquid nitrogen, transported on dry ice, and stored at 80C until required.
Preparation of Animal Chow
Powdered standard rodent chow (600 g, 5001 Lab Diet) was combined with
360 ml of water containing the appropriate amount of inhibitor. The amount
of added inhibitor was based on an average daily food consumption of
25 and 3 g, respectively, for rats and mice. After thorough mixing by hand,
themixture was passed though a pastamaker (Creative Technologies) and de-
hydrated for 36 hr at 37C. Food for the control animals was processed in an
identical manner. All food was stored at 20C until it was used. Chow con-
taining 60%energy from fat was obtained from TestDiet (58Y1). To incorporate
NButGT into this chow, the chow was warmed in a 37C oven for 30 min torved
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mixed in a Kitchen Aid mixer for 5 min to ensure equal distribution. The chow
was formed into cylinders, hardened at 20C, and cut into small chunks.
Food for control animals was treated identically. All food was stored
at 20C until it was used.
Intravenous Glucose Tolerance Test
Animals were fasted overnight (16 hr). Prior to initiating the experiment, resting
blood glucose levels were measured. To initiate the experiment, a 1 g$kg-1 tail
injection of glucose (50% in PBS) was delivered via either the tail vein over 30 s
or gavage. At various times, a small quantity of whole blood was used to
directly measure the concentration of glucose using a glucometer (Accu-
chek Advantage). As well, for studies in which insulin was monitored over
the course of the experiment, 200 ml of blood was collected from the saphe-
nous vein. These blood samples were stored on ice for 1 hr and then centri-
fuged at 2000 rpm for 10 min to obtain serum. Samples were aliquoted and
stored at 20C until further processing.
Tissue Homogenization
Tissues were homogenized by manual grinding frozen tissues into a fine
powder followed by homogenization in cell lysis buffer (50 mM NaH2PO4,
150 mM NaCl, 0.1% SDS, 1% NP-40, 0.25% sodium deoxycholate, protease
inhibitor tablet (Roche), 1 mMEDTA, and 1mMNButGT [pH 7.4]) using a tissue
homogenizer (T-18 Ultra-Turrax, Ika). Two hundred milligrams of the ground
tissue was dissolved in 2 ml of homogenization buffer. Insoluble cell debris
were removed by centrifugation at 17,900 rcf for 20 min and the resulting
supernatant was used immediately or stored at 20C until required.
Hyperinsulemic-Euglycemic Clamp
Animals were fasted overnight (16 hr). The following morning, animals were
anesthetized with a 60 mg$kg-1 intraperitoneal injection of sodium pentobar-
bital (Bimeda-MTC). The tail vein was then catheterized and sodium pentobar-
bital was delivered at a constant rate of 11 mg$kg-1$min-1 (in saline containing
20 U/ml heparin) for the remainder of the experiment in a total volume of 2 ml.
While unconscious, a catheter was inserted in the femoral artery and then
looped back into the femoral vein to create a blood sampling loop that mini-
mized blood loss (Lautt et al., 1998). For 2 hr, insulin (2.5 ml in total) (Eli Lilly)
and a 50% solution of glucose were delivered to the animal via the tail vein
catheter. Delivery of insulin was initiated 4 min prior to the glucose. Every
5 min, blood glucose levels were determined using a glucometer and the
glucose infusion rate was adjusted to maintain a level of 5 mM throughout
the experiment.
General Procedures
Details describing western blotting, immunoprecipitation, immunohistochem-
istry, serum analysis, large-scale synthesis of NButGT, pharmacokinetic anal-
ysis, and analysis of ganglioside levels are provided in the supporting material.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Experimental Procedures, Supplemental
Discussion, and two figures and can be found with this article online at
doi:10.1016/j.chembiol.2010.07.005.
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